Navigation Links
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Date:1/23/2013

patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety Information
Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
2. Cadence Pharmaceuticals to Host Analyst and Investor Day
3. Cadence to Open Finished Medical Device Facility
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
5. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
8. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
10. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 ... a condition that involves narrowing or blockage of ... heart rhythm problems, smoking, high cholesterol, and high ... arterial disease, atherosclerosis, and heart failure are some ... obstruction of blood vessels, especially coronary arteries, is ...
(Date:9/3/2015)... , Sept. 3, 2015 Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... presenting at the Morgan Stanley Global Healthcare Conference on ... Nevro management is scheduled to present at ... a live audio webcast, accessible in the "Investors" section ...
(Date:9/3/2015)... ALISO VIEJO, Calif. , Sept. ... ), a leading global pharmaceutical company, and AqueSys, ... focused on developing ocular implants that reduce intraocular ... they have entered into an agreement under which ...  Under the terms of the agreement, Allergan will ...
Breaking Medicine Technology:Global Cardiovascular Implants Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
... February 27 Novagali Pharma, a French,pharmaceutical ... first set of,data pertaining to Nova21027, its ... Novagali communicated about "Ocular ... conventional formulations of prostaglandin,analogues: an in vivo ...
... /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: ... of its new drug application ("NDA") for AFRESA(R), an ultra ... As previously announced, our internal goal was to submit the ... end of February. Based on editorial decisions made during ...
Cached Medicine Technology:Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma 2MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief (RTPR), makers ... rider David Mason has signed an official endorsement deal with the company. Originally from ... and his first bull at 15. He is an Australian bull riding champion, following ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Florida Companies to Watch for 2015 by economic development group GrowFL ... only 50 companies in the state selected for this prestigious award, which recognizes ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... by connecting accredited and institutional investors to real estate investment opportunities nationwide, today ... meet demand from both investors and sponsoring real estate companies. , ...
(Date:9/3/2015)... ... , ... Girl’s Night Out to benefit Core Compassion Project will be held ... in Monroe, North Carolina. The event food will be provided by Kate ... offers off-premise catering and event services from casual to elegant. They are also the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... provider of comprehensive eating disorder treatment for adults and adolescents struggling with ... Calinoiu, MD has joined the medical treatment team. As a Staff Psychiatrist, ...
Breaking Medicine News(10 mins):Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3
... were to be reclassified again, according to campaigners. The UK’s ... the drug //is connected to mental disorders. This may result ... three years. It had been classified as a Class C ... to the use of the drug has to be conducted, ...
... had been opened by the Beth Israel Medical Center in ... which can be avoided // , are taking place in ... medical circles. The diabetes centers in the city conduct boot ... spite of this the Type 2 diabetes cases have increased ...
... its intentions of establishing its presence in Ontario and ... 2007. //The Health Minister of the Province has said ... if any legislation is contravened. It has been opined ... belittling the public health system, and more attention will ...
... the age of information and health and combining the two ... for the Ministry of Health (MOH) China has announced that ... AID/HIV epidemic soon. ,In his clarification and statement, "Last year, ... World Health Organization (WHO) jointly estimated China's AIDS epidemic, and ...
... be on the decline. The current winter figures are only at between ... been on the decline since 2001. The threat from the avian flu ... immunity that the people in the country have gained to the H3N2 ... ,Most of the infected in the current winter are among ...
... revealed that two more people in China have succumbed to the ... // . The latest victims were a 35-year-old man and ... both the deaths. ,This does not mean that ... China, but it's a reminder that it is a very serious ...
Cached Medicine News:Health News:US Continues Its War On Diabetes 2Health News:Copeman Healthcare To Establish Private Clinics 2
A simple testing set for prescribing aspheric spectacle magnifiers. Redi-glaze lenses are available for instant dispensing which are cut and edged to fit our standard LVA frame....
... to 20 tilting tower ... the vertical, horizontal and ... option to offset the ... ,Filters include Cobalt blue; ...
... the outstanding optical system of the Keeler ... external fibre optic illumination system with diffuser ... digital camera. The result is an excellent ... the option of capturing stills or video ...
Assists in early recognition of changes in the macula and foveal areas., ,Only 6 patient responses required for diagnosis of functional disturbances, from small scotoma to distortions. Full instructi...
Medicine Products: